Bevacizumab plus capecitabine as later-line treatment for patients with metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines

There is an unmet medical need for later-line treatment options for patients with metastatic colorectal cancer (mCRC). Considering that, beyond progression, co-treatment with bevacizumab and cytotoxic chemotherapy showed less toxicity and a significant disease control rate, we aimed to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Bang, Yeong Hak, Kim, Jeong Eun, Lee, Ji Sung, Kim, Sun Young, Kim, Kyu-Pyo, Kim, Tae Won, Hong, Yong Sang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007566/
https://www.ncbi.nlm.nih.gov/pubmed/33782470
http://dx.doi.org/10.1038/s41598-021-86482-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8007566/
https://www.ncbi.nlm.nih.gov/pubmed/33782470
http://dx.doi.org/10.1038/s41598-021-86482-x

Ejemplares similares